Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study validated the VQ-Dermato, the first dermatology-specific quality of life instrument in French, and found it to be reliable, acceptable for routine use, and more responsive than the SF36.

This study found that QV Face Rescue Gel effectively induces collagen production, reduces UV-induced erythema, and decreases transepidermal water loss on sensitive facial skin, while being nonstinging, nonirritating, and noncomedogenic.

This review categorizes 59 modifications of the Dermatology Life Quality Index across multiple studies, highlighting the need for further validation of these customized health-related quality of life tools in dermatology.

In this study, researchers observed that quiescent mouse embryonic fibroblasts showed reduced glycolysis but increased TCA cycle flux and mitochondrial respiration, with these changes linked to metabolic reprogramming involving yes-associated protein inhibition and malate cycle modulation, which supports extracellular matrix protein synthesis.

In this experimental study, researchers found that Notopterygii rhizoma et radix (Qiang Huo) significantly alleviated psoriasis symptoms in mice and cell models, primarily by modulating the PI3K/Akt/mTOR pathway, indicating potential as a multi-target alternative therapy for psoriasis treatment.

In this study, Cyperus rotundus essential oil was found to have significantly better depigmenting effects than hydroquinone for treating axillary hyperpigmentation, with additional benefits in reducing inflammation and hair growth, making it a cost-effective and safe treatment option.

This study found that combining low-fluence Q-switched Nd: YAG laser and intense pulsed light led to faster and more effective melasma treatment compared to using the laser alone, though recurrence still occurred.

This study found that the Chinese version of the Polycystic Ovary Syndrome Quality of Life Questionnaire (Chi-PCOSQ) is sensitive to clinical changes and effectively assesses health-related quality of life in Chinese women with PCOS.

This article discusses the efficacy of different derma roller sizes compared to topical applications for administering QR678 Neo® in treating androgenetic alopecia, but provides no new clinical results.

QMSI effectively maps and quantifies drug distribution in skin tissues.

This study validated the Women's Androgenetic Alopecia Quality of Life questionnaire as a reliable and valid measure of health-related quality of life in women with alopecia areata.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This review summarizes existing literature on hydroxychloroquine for treating autoimmune-related hair disorders, highlighting its variable efficacy and emphasizing the need for individualized treatment decisions, but reports no new clinical results.

This study utilized a UHPLC-HRMS method to identify eight active pharmaceutical ingredients, such as ketoconazole and minoxidil, in 26 out of 100 analyzed cosmetic products.

This study developed the Women's Androgenetic Alopecia Quality of Life Questionnaire, which shows high reliability and internal consistency for assessing the impact of AGA on women's quality of life.

This study found that those with pityriasis rubra pilaris reported worse quality of life than patients with most other dermatologic conditions, impacting daily activities and emphasizing its severe life quality implications.

This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.

This review analyzes quality of life instruments for pediatric alopecia areata and reports inconsistencies in their coverage, suggesting the need for new tools to comprehensively assess all affected life aspects.

This study reported that a new bioinspired injectable hydrogel, CQCS@gel, showed promise as a multifunctional wound dressing by achieving rapid hemostasis and promoting the healing of infected skin wounds in both in vitro and in vivo tests.

In this study, the synthesis and testing of new pyrroloquinoline derivatives identified compound 7p, which showed low micromolar cytotoxic activity against MCF-7 and HeLa cells, highlighting its potential for development into a potent anticancer agent.

This study successfully adapted the Alopecia Areata Quality of Life Index Questionnaire into Turkish, finding it to be valid and reliable for assessing the quality of life in Turkish patients with alopecia areata.

This study found that patients with androgenetic alopecia, especially those who are young, less educated, and single, experience significantly reduced health-related quality of life.

In this in vitro study, Yifa Compound Prescription was reported to enhance human hair follicle growth and increase VEGF mRNA expression compared to blank serum.

Using a call center to collect data in a trial for eye disease in diabetics led to high response rates and very little missing information.

This study found that a new quercetin-loaded self-nanoemulsifying drug delivery system improved quercetin bioavailability by 149.8% compared to its suspension in rats.

This study found that platelet-rich plasma treatments improved quality of life for patients with pattern hair loss, as measured by decreased HAIRDEX scores in several domains over 3-5 months.

In a study using an androgenetic alopecia mouse model, researchers found that Qu-shi-yu-fa Decoction significantly promoted hair regeneration by enhancing follicle transition and activating key pathways, with potential therapeutic targets such as FOXN1 and TGM3 identified.

Platelet-rich plasma treatment for hair loss may improve patients' quality of life.

This review found that the only PCOS-specific quality of life measure, the PolyCystic Ovary Syndrome Questionnaire, has an incomplete development history and lacks some essential measurement properties for clinical trial use.